Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05325346 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
A Phase 1 study of Heparin-induced Thrombocytopenia, sponsored by Veralox Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05325346 is a Phase 1 study of Heparin-induced Thrombocytopenia that has completed, run by Veralox Therapeutics. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05325346, a Phase 1 study of Heparin-induced Thrombocytopenia, has completed, sponsored by Veralox Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of both agents in a population of healthy subjects.
Conditions Studied
Interventions
- DRUG VLX-1005
- DRUG Argatroban
Study Locations (1)
Nebraska
- Celerion, Inc. - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05325346
The ClinicalTrials.gov registry entry for NCT05325346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veralox Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heparin-induced Thrombocytopenia appearing as the primary indexed condition, and to 2 interventions - of which VLX-1005 is the first listed.
NCT05325346 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT05325346 about?
NCT05325346 is a clinical study titled "A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects". The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of both agents in a population of healthy subjects.
What is the current status of trial NCT05325346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-03-07. Estimated completion is 2022-04-14.
What conditions does trial NCT05325346 study?
This clinical trial studies the following conditions: Heparin-induced Thrombocytopenia.
What interventions are being tested in trial NCT05325346?
The interventions under investigation include: VLX-1005 (DRUG), Argatroban (DRUG).
Who is sponsoring clinical trial NCT05325346?
This trial is sponsored by Veralox Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05325346 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heparin-induced Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.